Climb Bio Net Profit Margin 2021-2024 | CLYM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Climb Bio net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Climb Bio net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.4B
Vertex Pharmaceuticals (VRTX)	$125.1B
Regeneron Pharmaceuticals (REGN)	$111.8B
Bristol Myers Squibb (BMY)	$106.8B
Gilead Sciences (GILD)	$105.9B
CSL (CSLLY)	$97.5B
GSK (GSK)	$81.1B
Alnylam Pharmaceuticals (ALNY)	$36.4B
Argenex SE (ARGX)	$32.5B
BioNTech SE (BNTX)	$28.6B
Biogen (BIIB)	$27.9B
Illumina (ILMN)	$23.7B
Moderna (MRNA)	$22.2B
BeiGene (BGNE)	$22.1B
Genmab (GMAB)	$15.7B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$13.1B
Insmed (INSM)	$12.9B
Vaxcyte (PCVX)	$12.6B
Incyte (INCY)	$12.6B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.7B
QIAGEN (QGEN)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.8B
Revolution Medicines (RVMD)	$8.2B
Repligen (RGEN)	$8B
Intra-Cellular Therapies (ITCI)	$7.8B
Ascendis Pharma (ASND)	$7.8B